Patienterne, der indgik i ARIES- 1 og - 2, var egnede til at indgå i et langtids, ublindet forlængelsesforsøg; ARIES- E (n = 383).
Patients enrolled into ARIES 1 and 2 were eligible to enter a long term open label extension study ARIES E (n=383).